Journal of Allergy and Clinical Immunology-In Practice最新文献

{"title":"Systematic Literature Review of Real-world Outcomes of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.","authors":"David J Jackson, Anat Shavit, Ning Ding, Michael Stokes, Stephanie Y Chen, Andrew Menzies-Gow, Augusto Vaglio, Michael E Wechsler","doi":"10.1016/j.jaip.2025.08.028","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.08.028","url":null,"abstract":"<p><strong>Background: </strong>Several real-world cohorts and numerous case reports investigating benralizumab outcomes in eosinophilic granulomatosis with polyangiitis have been published. These studies complement the limited clinical trial data available by providing early insights on benralizumab use in a broader, real-world population.</p><p><strong>Objective: </strong>The objective of this systematic literature review (SLR) was to provide an overview of the real-world outcomes of benralizumab in EGPA.</p><p><strong>Methods: </strong>SLR was conducted to identify articles and abstracts (from January 1, 2017, through January 12, 2024) reporting eosinophilic granulomatosis with polyangiitis and asthma outcomes in patients with eosinophilic granulomatosis with polyangiitis receiving benralizumab.</p><p><strong>Results: </strong>Thirty-nine studies (seven cohort/32 case reports) were included (N=306/N=41 patients). Mean age ranged from 42 to 56 years; anti-neutrophil cytoplasmic antibody positivity varied from 18% to 59%. Nearly all publications examined benralizumab at the dosage approved for severe eosinophilic asthma. Prior mepolizumab use was reported in 12%-46% of patients. Reasons for switching to benralizumab included lack of (or insufficient) response and persistent symptoms. Remission rates were reported in three cohorts at 12 months (46%-69%) and two cohorts at 24 months (66%-71%). One cohort reported a trend of lower remission rates among patients previously treated with mepolizumab (37% vs. 60%) compared to not (p=0.09). Significant oral corticosteroid-sparing effects were observed, and oral corticosteroid use was completely discontinued in 32%-68% of patients.</p><p><strong>Conclusion: </strong>In real-world reports, benralizumab was associated with significant oral corticosteroid-sparing effects and clinical remission in a significant proportion of patients with eosinophilic granulomatosis with polyangiitis.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging systemic treatments for asthma and allergic diseases: New tricks, same dog?","authors":"Alessandra Tomasello, Stanley J Szefler, Katherine N Cahill","doi":"10.1016/j.jaip.2025.08.022","DOIUrl":"10.1016/j.jaip.2025.08.022","url":null,"abstract":"<p><p>Asthma and allergic diseases are heterogeneous conditions driven by complex immunological pathways, with type 2 (T2) inflammation being a key but not exclusive component. Advances in immunology have spurred interest in a breadth of mechanisms and innovative therapeutic strategies, including novel targets, extended dosing intervals, and combined-target therapies. This clinical commentary provides a critical overview of ongoing clinical trials and emerging evidence supporting the use of these therapies in asthma and other allergic conditions. We evaluate and summarize emerging systemic treatments across four mechanistic categories: T2 cytokine inhibitors, alarmin blockers, effector cell modulators, and therapies targeting unconventional, broad immune, and non-T2 inflammation pathways. For each category, we present balanced perspectives on therapeutic potential and limitations. While certain therapies demonstrate promise, particularly in T2-high phenotypes, challenges remain in identifying predictive biomarkers, understanding long-term safety, and addressing non-T2 mechanisms. The commentary concludes with outcomes measurement recommendations and outlines urgent knowledge gaps requiring targeted research to optimize precision treatment strategies for diverse patient populations with asthma and allergic diseases.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic rhinosinusitis in 292 adults with primary antibody deficiencies.","authors":"Uma Rao, Meghan Dutt, Sudhir Gupta, Yesim Yilmaz Demirdag","doi":"10.1016/j.jaip.2025.08.023","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.08.023","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from the first 820 patients from the Brazilian Multicenter Registry of Hereditary Angioedema: the key role of genetic testing and targeted therapies.","authors":"Mariana P L Ferriani, José Eduardo S Lemos, L Karla Arruda, Fernanda L Nunes, Marina M Dias, Maitê L Kolarik, Persio Roxo-Junior, Maria Fernanda Ferraro, Maria Eduarda T Zanetti, Faradiba S Serpa Fs, Herberto J Chong Neto, Fernanda G Minafra, Solange O R Valle, Régis A Campos, Jane da Silva, Eli Mansour, Rozana F Gonçalves, Eliana C Toledo, Fernanda C Marcelino, Iramirton F Moreira, Adriana Azoubel-Antunes, Janaira F S Ferreira, Gabriela A C Dias, Marcelo V Aun, Ana Paula, Maria Luiza O Alonso, Vanessa A Batigalia, Clarissa Ltsv Tavares, Albertina V Capelo, Therezinha R Moyses, Nelson A Rosário Filho, Lucca Np Jannuzzi, Nyla Tml Fragnan, Joanemile P de Figueiredo, Joice T da Fonseca, Ana Julia R Teixeira, Nayara Mf Nasser, Natasha R Ferraroni, Leonardo O Mendonça, Márcia T Iwashita, Alex I F Prado, Melissa T Tumelero, Julianne A Machado, Tsukiyo O Kamoi, Luciana M Ferrel, Adriana Msc Barbosa, Caroline Gfb de Moraes, Tatielly Kruk, Mariana R Figueiredo, Maria Stela Y Moraes, Adriana S Moreno, Luana Sm Maia, Fabiola Traina, Patricia C Ruy Pc, João B Pesquero, Konrad Bork, Sven Cichon, Davi C Aragon, Pedro Giavina-Bianchi, Anete S Grumach As","doi":"10.1016/j.jaip.2025.08.026","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.08.026","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is a rare autosomal dominant disorder with a prevalence of 1:50,000 individuals. Delayed diagnosis and deaths from asphyxia still occur.</p><p><strong>Objective: </strong>To identify knowledge and management gaps regarding clinical, genetic, and therapeutic aspects of HAE in Brazil, aiming to improve patient care and outcomes.</p><p><strong>Methods: </strong>A Brazilian multicenter HAE Registry was established, with patients' data included by treating physicians using the REDCap platform.</p><p><strong>Results: </strong>Of the 820 HAE patients enrolled, 68.8% were female. Most (72.4%) presented HAE due to C1INH deficiency (HAE-C1INH), whereas 19.4% had HAE with normal C1INH caused by variants in the F12 gene (HAE-FXII). Onset of symptoms occurred earlier in HAE-C1INH as compared to HAE-FXII (mean 11.2 years versus 19.4 years, respectively), and time for diagnosis was shorter in patients younger than 18 years-old, as compared to those 18 years-old and older (mean 1.8 years versus 14.5 years, respectively). Regarding treatment, 52.8% received first-line on-demand therapies (Icatibant or plasma-derived C1INH). Only 4.8% used first-line options for long-term prophylaxis (LTP), such as lanadelumab or subcutaneous/intravenous pdC1INH. Attenuated androgens were used for LTP in 52% of patients, with adverse effects reported for 34.8%.</p><p><strong>Conclusion: </strong>Brazilian patients with HAE share common aspects with global patients, including predominance in women, and HAE-C1INH as the most common subtype. Available genetic testing allowed for identification of a notable proportion of HAE-FXII (19.4% of the patients). Despite recent advances, access to first-line therapies for long-term prophylaxis of HAE attacks remains limited.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Original Article Highlights From This Issue","authors":"","doi":"10.1016/S2213-2198(25)00779-2","DOIUrl":"10.1016/S2213-2198(25)00779-2","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages A11-A15"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Disease Severity Index for Patients With Cold Urticaria","authors":"Tatjana Altunergil MD ,&nbsp;Manuel P. Pereira MD, PhD ,&nbsp;Sabine Altrichter MD ,&nbsp;Annika Gutsche MSc ,&nbsp;Dalia M. Ahsan MD ,&nbsp;Lena Fox ,&nbsp;Eva Grekowitz MD ,&nbsp;Hanna Bonnekoh MD ,&nbsp;Karsten Weller MD ,&nbsp;Marcus Maurer MD ,&nbsp;Pascale Salameh PhD ,&nbsp;Dorothea Terhorst-Molawi MD","doi":"10.1016/j.jaip.2025.04.047","DOIUrl":"10.1016/j.jaip.2025.04.047","url":null,"abstract":"<div><h3>Background</h3><div>Cold urticaria (ColdU) is a common type of chronic inducible urticaria where cold induces wheals and/or angioedema, with a wide range of disease severity, from very mild to life-changing and life-threatening, based on symptoms, day-to-day burden, general response to therapies, the need for cold avoidance, and the use of emergency treatment. There are no validated instruments to objectively assess disease severity in patients with ColdU.</div></div><div><h3>Objective</h3><div>To develop and validate a disease-specific Severity Index for ColdU (SICU).</div></div><div><h3>Methods</h3><div>The development of the SICU followed 4 phases: (1) conceptual framework, (2) item generation, (3) item reduction, and (4) final editing. Seven and eight patients were interviewed in the item generation phase and in the item reduction phase, respectively. Then, a validation study with 75 patients was performed, which included construct, structural, convergent, and known-group validity assessments as well as the characterization of reliability (internal consistency and test-retest).</div></div><div><h3>Results</h3><div>The preliminary tool consisted of 24 items. After item reduction, the final SICU included 13 items and 4 domains: “trigger factors,” “signs and symptoms,” “quality of life,” and “therapy and efficiency.” The validation study revealed appropriate structural and construct validity with excellent measures of sample adequacy, appropriate convergent validity, as well as an adequate known-group validity, high internal consistency, and high test-retest reliability.</div></div><div><h3>Conclusions</h3><div>The SICU is the first validated disease-specific patient-reported outcome measure (PROM) for assessing ColdU disease severity. This PROM will facilitate patient care by evaluating disease severity and consequently better informing physicians and patients on an appropriate therapeutic approach.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2338-2348.e9"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-thyroid peroxidase antibody (anti-TPO antibodies) is higher in children with chronic urticaria who require omalizumab","authors":"Zainab Alsaffar MD ,&nbsp;Roy Khalaf ,&nbsp;Abdulaziz Alrafiaah MD ,&nbsp;Sarah D. Mohamed ,&nbsp;Elena Netchiporouk MD ,&nbsp;Michael Fein MD ,&nbsp;John Sampalis PhD ,&nbsp;Moshe Ben-Shoshan MD","doi":"10.1016/j.jaip.2025.04.021","DOIUrl":"10.1016/j.jaip.2025.04.021","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2496-2498"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative diagnostic performance of mx4-IgE versus species-specific IgE for identifying allergic bronchopulmonary aspergillosis","authors":"Ritesh Agarwal MD, DM ,&nbsp;Inderpaul Singh Sehgal MD, DM ,&nbsp;Valliappan Muthu MD, DM ,&nbsp;Sahajal Dhooria MD, DM ,&nbsp;Kuruswamy Thurai Prasad MD, DM ,&nbsp;Mani Singh BSc ,&nbsp;Shivaprakash M. Rudramurthy MD ,&nbsp;Ashutosh Nath Aggarwal MD, DM ,&nbsp;Mandeep Garg DM ,&nbsp;Arunaloke Chakrabarti MD","doi":"10.1016/j.jaip.2025.05.038","DOIUrl":"10.1016/j.jaip.2025.05.038","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2509-2511.e1"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Calculator of the Clinical Response to Antihistamines in Chronic Urticaria: External Validation","authors":"Jorge Sánchez MD, MSc, EAC, PhD ,&nbsp;Ana Caraballo MD ,&nbsp;Ivan Cherrez MD, MSc, PhD ,&nbsp;Elizabeth García MD, EAC ,&nbsp;Jose-Ignacio Larco MD ,&nbsp;German Ramon MD ,&nbsp;Margarita Velasquez MD, PhD ,&nbsp;Fabian Jaimes MD, MSc, PhD","doi":"10.1016/j.jaip.2025.05.051","DOIUrl":"10.1016/j.jaip.2025.05.051","url":null,"abstract":"<div><h3>Background</h3><div>Antihistamines (antiH1) are the first-line treatment for chronic spontaneous urticaria (CSU), but 40% to 60% of patients do not achieve clinical control with this therapy. Early identification of the non-responder patients could undergo prompt initiation of other therapies.</div></div><div><h3>Objective</h3><div>To achieve external validation of a prognostic calculator of clinical response to antiH1 in adult patients with CSU.</div></div><div><h3>Methods</h3><div>The prognostic calculator consisted of five variables easily accessible during clinical appointments (age, angioedema, anxiety or depression, duration of the disease, nonsteroidal anti-inflammatory drug hypersensitivity, and urticaria activity score (UAS). Patients with CSU from four countries were evaluated before and after antihistamine administration. Calibration and discrimination were used to evaluate prognostic accuracy. The main outcome, clinical response to antihistamines, was evaluated with the UAS for 7 days (UAS7). Control was defined as a UAS7 score less than 6 and no control was defined as UAS7 greater than 7 points.</div></div><div><h3>Results</h3><div>A total of 542 patients were included. The prognostic model performance demonstrated consistency (accuracy of 78.6%; Hosmer-Lemeshow, 0.89; area under the curve, 0.829). The model correctly predicted 82.9% of patients with UAS7 greater than 7 and 72.7% of patients with UAS7 less than 6. Patients without antiH1 control had more frequent autoimmune disease and inducible urticaria, and patients with antiH1 control had higher levels of total IgE and a higher frequency of IgE anti-thyroperoxidase, IgE anti-eosinophil peroxidase and IgE anti-eosinophil cationic protein.</div></div><div><h3>Conclusion</h3><div>This prognostic calculator was demonstrated to be a useful tool in clinical practice for an early personalized therapeutic approach according to the individual probability of response with antihistamines, potentially reducing time with suboptimal treatments.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2361-2369"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A framework to define an occasion of asthma reliever inhaler use","authors":"Jonathan Noble MBBS ,&nbsp;Orlagh Bean MBBS ,&nbsp;Ross Sayers MBBS ,&nbsp;Ryan Cullen MBChB ,&nbsp;Louis Kirton MBChB ,&nbsp;Allie Eathorne MAppStat ,&nbsp;Mark Weatherall FRACP ,&nbsp;Richard Beasley DSc","doi":"10.1016/j.jaip.2025.05.039","DOIUrl":"10.1016/j.jaip.2025.05.039","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2512-2514.e1"},"PeriodicalIF":6.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}